Tantoy Ilufredo Y, Cataldo Janine K, Aouizerat Bradley E, Dhruva Anand, Miaskowski Christine
Author Affiliations: Department of Physiological Nursing, School of Nursing (Mr Tantoy and Drs Cataldo, Aouizerat, and Miaskowski), School of Medicine (Dr Dhruva), and Institute for Human Genetics (Dr Aouizerat), University of California, San Francisco.
Cancer Nurs. 2016 Nov-Dec;39(6):437-445. doi: 10.1097/NCC.0000000000000343.
Patients with colorectal cancer (CRC) rarely experience a single symptom associated with their disease and its treatment.
Purpose of this literature review was to summarize the current state of knowledge of multiple co-occurring symptoms in CRC patients who received chemotherapy (CTX) alone or CTX with targeted therapies.
Comprehensive literature search was conducted from 1990 to 2014. These studies were evaluated in terms of the occurrence of multiple co-occurring symptoms in CRC patients who received CTX alone or CTX with targeted therapies; the most common symptom assessment and quality of life (QOL) instruments used; and the associations identified between select demographic and treatment characteristics, QOL, and multiple co-occurring symptoms.
Only 5 studies met this review's inclusion criteria. Two studies compared symptoms in patients who received CTX alone or CTX with targeted therapies, and only 1 study reported on symptom occurrence. Of the 5 studies identified, only 2 used the same instrument to assess symptoms, and only 2 studies evaluated for associations between demographic and treatment characteristics and symptom burden, as well as QOL outcomes.
Given the larger number of patients with CRC, as well as the increased number of CRC patients who will receive targeted therapies with or without CTX, future studies need to describe the occurrence, severity, and distress of multiple co-occurring symptoms and their impact on CRC patients' QOL.
To deliver effective symptom management interventions, the most common, severe, and distressing symptoms that CRC patients experience need to be identified.
结直肠癌(CRC)患者很少仅经历与疾病及其治疗相关的单一症状。
本综述的目的是总结接受单纯化疗(CTX)或CTX联合靶向治疗的CRC患者中多种并发症状的现有知识状态。
对1990年至2014年进行了全面的文献检索。根据接受单纯CTX或CTX联合靶向治疗的CRC患者中多种并发症状的发生情况、最常用的症状评估和生活质量(QOL)工具,以及选定的人口统计学和治疗特征、QOL与多种并发症状之间的关联对这些研究进行评估。
只有5项研究符合本综述的纳入标准。两项研究比较了接受单纯CTX或CTX联合靶向治疗的患者的症状,只有1项研究报告了症状的发生情况。在确定的5项研究中,只有2项使用相同的工具评估症状,只有2项研究评估了人口统计学和治疗特征与症状负担以及QOL结果之间的关联。
鉴于CRC患者数量较多,以及接受或不接受CTX的靶向治疗的CRC患者数量增加,未来的研究需要描述多种并发症状的发生情况、严重程度和困扰程度及其对CRC患者QOL的影响。
为了提供有效的症状管理干预措施,需要确定CRC患者经历的最常见、最严重和最困扰的症状。